MEP90508A - New pharmaceutical composition - Google Patents

New pharmaceutical composition

Info

Publication number
MEP90508A
MEP90508A MEP-905/08A MEP90508A MEP90508A ME P90508 A MEP90508 A ME P90508A ME P90508 A MEP90508 A ME P90508A ME P90508 A MEP90508 A ME P90508A
Authority
ME
Montenegro
Prior art keywords
pharmaceutical composition
new pharmaceutical
relates
present
composition
Prior art date
Application number
MEP-905/08A
Other languages
English (en)
Croatian (hr)
Inventor
Pierre Barbier
Paul Hadvary
Hans Lengsfeld
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169384&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP90508(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of MEP90508A publication Critical patent/MEP90508A/xx
Publication of ME00671B publication Critical patent/ME00671B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MEP-2008-905A 2000-07-28 2001-07-19 Nova farmaceutska smeša ME00671B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00116393 2000-07-28
PCT/EP2001/008363 WO2002009815A2 (en) 2000-07-28 2001-07-19 New pharmaceutical composition

Publications (2)

Publication Number Publication Date
MEP90508A true MEP90508A (en) 2011-12-20
ME00671B ME00671B (me) 2011-12-20

Family

ID=8169384

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-905A ME00671B (me) 2000-07-28 2001-07-19 Nova farmaceutska smeša

Country Status (38)

Country Link
US (5) US6756364B2 (xx)
EP (1) EP1307264B1 (xx)
JP (2) JP4265911B2 (xx)
KR (1) KR100572785B1 (xx)
CN (1) CN100423715C (xx)
AR (1) AR033548A1 (xx)
AT (1) ATE279961T1 (xx)
AU (2) AU2001289699B2 (xx)
BR (1) BR0112799B1 (xx)
CA (1) CA2416901C (xx)
CZ (1) CZ302087B6 (xx)
DE (1) DE60106623T2 (xx)
EC (1) ECSP034450A (xx)
EG (1) EG24357A (xx)
ES (1) ES2230362T3 (xx)
GT (1) GT200100152A (xx)
HK (1) HK1058636A1 (xx)
HR (1) HRP20030029B1 (xx)
HU (1) HU229292B1 (xx)
IL (2) IL154008A0 (xx)
JO (1) JO2320B1 (xx)
MA (1) MA26937A1 (xx)
ME (1) ME00671B (xx)
MX (1) MXPA03000771A (xx)
MY (1) MY127247A (xx)
NO (1) NO330546B1 (xx)
NZ (1) NZ523684A (xx)
PA (1) PA8523201A1 (xx)
PE (1) PE20020336A1 (xx)
PL (1) PL204443B1 (xx)
PT (1) PT1307264E (xx)
RS (1) RS50397B (xx)
RU (1) RU2241462C2 (xx)
SI (1) SI1307264T1 (xx)
TW (1) TWI275395B (xx)
UY (1) UY26860A1 (xx)
WO (1) WO2002009815A2 (xx)
ZA (1) ZA200300456B (xx)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0112799B1 (pt) * 2000-07-28 2017-10-24 Hoffmann La Roche Pharmaceutical composition, process for the preparation of the same, use of a lipase inhibitor and a bilic acid sequestrant
WO2002009814A2 (en) * 2000-07-28 2002-02-07 F. Hoffmann-La Roche Ag New use of lipase inhibitors
US7033373B2 (en) 2000-11-03 2006-04-25 Satiety, Inc. Method and device for use in minimally invasive placement of space-occupying intragastric devices
US6558400B2 (en) 2001-05-30 2003-05-06 Satiety, Inc. Obesity treatment tools and methods
BRPI0309406B1 (pt) * 2002-04-26 2017-04-11 Hoffmann La Roche composição farmacêutica, processo para preparar a referida composição, kit para tratamento de obesidade e uso da referida composição na fabricação de composições úteis para o tratamento e prevenção de obesidade
US6746460B2 (en) 2002-08-07 2004-06-08 Satiety, Inc. Intra-gastric fastening devices
US7033384B2 (en) 2002-08-30 2006-04-25 Satiety, Inc. Stented anchoring of gastric space-occupying devices
US7214233B2 (en) 2002-08-30 2007-05-08 Satiety, Inc. Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach
EP1545562B1 (en) * 2002-09-09 2006-04-19 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Branched alpha-glucans for weight management
US7220237B2 (en) 2002-10-23 2007-05-22 Satiety, Inc. Method and device for use in endoscopic organ procedures
PT2368553E (pt) 2003-04-08 2015-03-03 Progenics Pharm Inc Formulações farmacêuticas contendo metilnaltrexona
US7175638B2 (en) 2003-04-16 2007-02-13 Satiety, Inc. Method and devices for modifying the function of a body organ
US7097650B2 (en) * 2003-10-14 2006-08-29 Satiety, Inc. System for tissue approximation and fixation
US7914543B2 (en) 2003-10-14 2011-03-29 Satiety, Inc. Single fold device for tissue fixation
US8025794B2 (en) * 2003-12-19 2011-09-27 Shell Oil Company Systems, methods, and catalysts for producing a crude product
US20050177176A1 (en) 2004-02-05 2005-08-11 Craig Gerbi Single-fold system for tissue approximation and fixation
WO2005079673A2 (en) 2004-02-13 2005-09-01 Satiety, Inc. Methods for reducing hollow organ volume
CA2547934C (en) * 2004-02-19 2013-05-21 Abbott Laboratories Methods of using gamma cyclodextrin to control blood glucose and insulin secretion
EP1725194B1 (en) 2004-02-27 2018-01-17 Ethicon Endo-Surgery, Inc. Methods and devices for reducing stomach volume
US9028511B2 (en) 2004-03-09 2015-05-12 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US8252009B2 (en) 2004-03-09 2012-08-28 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
US8449560B2 (en) 2004-03-09 2013-05-28 Satiety, Inc. Devices and methods for placement of partitions within a hollow body organ
US8628547B2 (en) 2004-03-09 2014-01-14 Ethicon Endo-Surgery, Inc. Devices and methods for placement of partitions within a hollow body organ
EP1750627B1 (en) 2004-03-26 2018-10-10 Ethicon Endo-Surgery, Inc. System for reducing stomach volume
US20050276781A1 (en) * 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use
WO2006035296A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for the preparation of an orlistat derivative useful as reference standard in the determination of the purity of orlistat and process for the preparation of orlistat
US20060106288A1 (en) 2004-11-17 2006-05-18 Roth Alex T Remote tissue retraction device
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN104248763A (zh) * 2005-03-07 2014-12-31 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
JP5044398B2 (ja) * 2005-06-09 2012-10-10 武田薬品工業株式会社 固形製剤
WO2006134591A2 (en) * 2005-06-13 2006-12-21 Yeda Research And Development Co. Ltd. Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
US20090162314A1 (en) * 2005-11-08 2009-06-25 Huval Chad C Magnesium-Containing Polymers for the Treatment of Hyperphosphatemia
NZ569756A (en) * 2005-12-12 2011-07-29 Allaccem Inc Methods and systems for preparing antimicrobial films and coatings utilising polycyclic bridged ammonium salts
EP1803714A1 (en) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing crystalline forms of orlistat
EP1984328A2 (en) * 2006-01-25 2008-10-29 Yeda Research And Development Co., Ltd. A process for preparing allylmercaptocaptopril (cpssa) and related asymmetrical disulfides
CN101404982A (zh) * 2006-02-14 2009-04-08 特瓦制药工业有限公司 脂族胺聚合物的药物制剂和它们的制造方法
EP1818048B1 (en) * 2006-02-14 2009-01-07 Teva Pharmaceutical Industries, Inc. Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
KR20090051240A (ko) * 2006-09-01 2009-05-21 유에스브이 리미티드 세벨라머 염산염의 제조방법 및 그의 제형
US20080069906A1 (en) * 2006-09-18 2008-03-20 Thompson Ronald J Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor
US7662373B2 (en) * 2006-09-18 2010-02-16 Thompson Ronald J Method and composition of a medicament to decrease the adverse events of Olistat, an oral lipase inhibitor
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
WO2008070308A2 (en) * 2006-10-24 2008-06-12 Thompson Md Ronald J Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, an oral lipase inhibitor, and a method with formulations to concurrently reduce fracture risk and insure appropriate fatsoluble vitamin supplementation when using orlistat, an oral lipase inhibitor, and a method o
CA2673665C (en) * 2006-12-22 2017-03-21 Ironwood Pharmaceuticals, Inc. Method and compositions for treating esophageal disorders
EP1944025A1 (en) * 2007-01-09 2008-07-16 Ranbaxy Laboratories Limited Stable pharmaceutical compositions of orlistat
WO2008103847A2 (en) 2007-02-21 2008-08-28 Allaccem, Incorporated Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
PE20090700A1 (es) 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
CA2865389A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
EP2139890B1 (en) 2007-03-29 2014-06-25 Wyeth LLC Peripheral opioid receptor antagonists and uses thereof
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US20090074833A1 (en) * 2007-08-17 2009-03-19 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling bone resorption
WO2009050720A1 (en) * 2007-10-15 2009-04-23 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
US20100004218A1 (en) * 2008-06-20 2010-01-07 Whiteford Jeffery A Bridged polycyclic compound based compositions for renal therapy
US20100016270A1 (en) * 2008-06-20 2010-01-21 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling cholesterol levels
RU2011112694A (ru) * 2008-09-02 2012-10-10 Юсв Лимитед (In) Сшитые полимеры
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20100330175A1 (en) * 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
WO2011075539A2 (en) * 2009-12-18 2011-06-23 Satiogen Pharmaceuticals, Inc. Treatment of obesity or diabetes with bile acid sequestrants
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN103260625B (zh) 2010-11-08 2016-01-06 阿尔比里奥公司 用于治疗肝脏疾病的ibat抑制剂
WO2013049595A1 (en) * 2011-09-29 2013-04-04 Ethicon Endo-Surgery, Inc. Methods and compositions of bile acids
CA2853285C (en) 2011-10-28 2020-05-05 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP2591768B1 (en) * 2011-11-14 2014-07-16 Deva Holding Anonim Sirketi Single unit dosage formulations of sevelamer and fat soluble vitamins and surface active agents
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
JP6421124B2 (ja) 2012-11-06 2018-11-07 シグリッド・セラピューティクス・アーベー 医薬有効成分又は食品有効成分としての使用のための多孔質シリカ材料
CN104955446B (zh) 2012-12-21 2017-08-22 财团法人卫生研究院 用于吸收油脂的中孔洞硅奈米粒子
RU2552926C1 (ru) * 2014-06-23 2015-06-10 Общество с ограниченной ответственностью "ПРОМОМЕД" Фармацевтическая комбинация для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, и способ лечения на ее основе
KR102560954B1 (ko) 2014-06-25 2023-07-31 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
JP6830969B2 (ja) * 2016-02-09 2021-02-17 アルビレオ・アクチボラグ コレスチラミンペレット剤及びその調製のための方法
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
EP3664781A1 (en) 2017-08-09 2020-06-17 Albireo AB Cholestyramine granules, oral cholestyramine formulations and use thereof
US11389545B2 (en) * 2018-01-09 2022-07-19 Aqua Regenerative Therapies Llc Bioactive nanoparticles and methods for making same
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
CN108685848B (zh) * 2018-08-13 2020-09-01 中山万汉制药有限公司 一种奥利司他口服乳剂及其制备方法
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN111297826B (zh) * 2020-04-20 2021-08-03 鲁南制药集团股份有限公司 一种稳定的奥利司他胶囊及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
IT1052819B (it) * 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DE3414609C1 (de) * 1984-04-18 1985-06-20 Daimler-Benz Ag, 7000 Stuttgart Vorrichtung zur Beeinflussung eines Kuehlluftstromes
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5344453A (en) * 1991-05-30 1994-09-06 Boston Medical Products, Inc. Thyroplasty implant
US5616570A (en) * 1991-10-18 1997-04-01 Lange, Iii; Louis G. Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
TW381025B (en) 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5569452A (en) * 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5545414A (en) * 1995-03-22 1996-08-13 Abbott Laboratories Cholesterol lowering food product
JP3832871B2 (ja) * 1995-04-03 2006-10-11 日本製粉株式会社 リパーゼ阻害剤
DK0815857T3 (da) 1995-12-26 2005-01-24 Suntory Ltd Anti-adipöst middel indeholdende procyanidin som den aktive ingrediens
US5612026A (en) * 1996-01-25 1997-03-18 The Procter & Gamble Company Cholesterol lowering drink mix compositons
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
JP3807464B2 (ja) 1997-11-17 2006-08-09 康二 嘉島 肥満防止剤
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
PL193452B1 (pl) 1998-01-09 2007-02-28 Genzyme Corp Kompozycja farmaceutyczna albo zestaw do leczenia otyłości i/lub zmniejszania wchłaniania tłuszczu u ssaka oraz zastosowania
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
FI113356B (fi) 1998-05-20 2004-04-15 Upm Kymmene Corp Pakkauksenmuodostuslaite
CA2340056C (en) * 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
ES2217797T3 (es) * 1998-08-14 2004-11-01 F. Hoffmann-La Roche Ag Vinileteres heterociclicos contra trastornos neurologicos.
EP1112063A4 (en) 1998-09-08 2009-05-13 Smithkline Beecham Corp TABLETS BASED ON AN LPSTATINE DERIVATIVE AND SOLUBLE FIBERS
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
WO2000043036A2 (en) 1999-01-22 2000-07-27 Hunza Di Maria Carmela Marazzita S.A.S. Lipoprotein complexes and compositions containing them
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
BR0112799B1 (pt) * 2000-07-28 2017-10-24 Hoffmann La Roche Pharmaceutical composition, process for the preparation of the same, use of a lipase inhibitor and a bilic acid sequestrant

Also Published As

Publication number Publication date
DE60106623D1 (de) 2004-11-25
HK1058636A1 (en) 2004-05-28
GT200100152A (es) 2002-05-16
JP4265911B2 (ja) 2009-05-20
US6756364B2 (en) 2004-06-29
HRP20030029B1 (en) 2005-06-30
PE20020336A1 (es) 2002-05-08
US8071571B2 (en) 2011-12-06
CZ302087B6 (cs) 2010-10-06
ES2230362T3 (es) 2005-05-01
ATE279961T1 (de) 2004-11-15
HUP0301281A3 (en) 2005-05-30
PA8523201A1 (es) 2002-10-24
HUP0301281A2 (hu) 2003-08-28
DE60106623T2 (de) 2006-02-02
PL204443B1 (pl) 2010-01-29
NO20030418L (no) 2003-01-27
US20040105838A1 (en) 2004-06-03
CZ2003582A3 (cs) 2004-02-18
KR20030029796A (ko) 2003-04-16
MXPA03000771A (es) 2003-06-04
SI1307264T1 (en) 2005-02-28
US20050136030A1 (en) 2005-06-23
WO2002009815A3 (en) 2002-04-18
AR033548A1 (es) 2003-12-26
MA26937A1 (fr) 2004-12-20
JP2009073833A (ja) 2009-04-09
IL154008A0 (en) 2003-07-31
JP2004505067A (ja) 2004-02-19
NO330546B1 (no) 2011-05-16
PL366105A1 (en) 2005-01-24
WO2002009815A2 (en) 2002-02-07
US20100203032A1 (en) 2010-08-12
CN1444495A (zh) 2003-09-24
MY127247A (en) 2006-11-30
US20020035089A1 (en) 2002-03-21
EP1307264A2 (en) 2003-05-07
UY26860A1 (es) 2002-01-31
ECSP034450A (es) 2003-03-10
EG24357A (en) 2009-03-04
CN100423715C (zh) 2008-10-08
RU2241462C2 (ru) 2004-12-10
ME00671B (me) 2011-12-20
AU8969901A (en) 2002-02-13
HU229292B1 (en) 2013-10-28
JO2320B1 (en) 2005-09-12
YU5003A (sh) 2006-01-16
NO20030418D0 (no) 2003-01-27
BR0112799A (pt) 2003-07-01
HRP20030029A2 (en) 2004-02-29
BR0112799B1 (pt) 2017-10-24
ZA200300456B (en) 2004-04-16
IL154008A (en) 2011-12-29
TWI275395B (en) 2007-03-11
RS50397B (sr) 2009-12-31
CA2416901C (en) 2007-07-03
NZ523684A (en) 2005-04-29
CA2416901A1 (en) 2002-02-07
EP1307264B1 (en) 2004-10-20
US20060269510A1 (en) 2006-11-30
PT1307264E (pt) 2005-02-28
AU2001289699B2 (en) 2006-06-01
KR100572785B1 (ko) 2006-04-19

Similar Documents

Publication Publication Date Title
MEP90508A (en) New pharmaceutical composition
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
ATE294158T1 (de) Ein monoether von probucol und methoden zur hemmung der vcam-1 expression
WO2001062280A3 (en) Lipase-containing composition and methods of use thereof
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
HUP0103160A2 (hu) Pulmonalis betegségek kezelésére alkalmas PDE4 inhibítort tartalmazó gyógyászati készítmények
DZ3402A1 (fr) Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
WO2003072593A3 (en) Bone targeting peptides
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
ATE432074T1 (de) Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
BR0008382A (pt) Formulação de liberação controlada para tratamento de copd
BR0210493A (pt) Composição, e, método para remover cerume humano
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DK1276722T3 (da) Naphthamidin-urokinaseinhibitorer
DK1144348T3 (da) LTA4-hydrolaseinhibitorer
DE60111921D1 (de) Dextrinhaltige zusammensetzungen zur vermeidung von adhäsionen
ATE224735T1 (de) Mittel zur spezifischen hemmung osteoklastärer knochenresorption